PDCD1LG2 and neoplasm: PD‐1 is a common receptor of PD‐L1 and PD‐L2, whereas simultaneous blocking of PD‐1 and PD‐L2 obtained preferable tumor inhibition than anti‐PD‐1 alone, implying another binding partner of PD‐L2 involving these processes.